Navigation Links
Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes
Date:4/26/2010

TAMPA, Fla., April 26 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic biopharmaceutical company, announced today that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially available.  Zirgan™, which was approved by the U.S. Food and Drug Administration in September 2009, is a topical ophthalmic antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers).  

(Logo: http://www.newscom.com/cgi-bin/prnh/20100426/FL92821LOGO )

"Sirion began shipping Zirgan™ to drug distributors and retail chains today," said Barry Butler, of Sirion Therapeutics, Inc. "Healthcare professionals can begin prescribing Zirgan™ and pharmacies should be able to fill the prescription immediately or within 24 hours if the pharmacy has to order it from their drug distributor.  We have received an overwhelming number of inquiries regarding Zirgan™ and its availability and are proud to be providing eye care professionals with the first innovation in ocular antiviral therapy in the US in over 30 years."

Zirgan™ is a topical ophthalmic gel formulation that appears clear and colorless and is supplied in a 5 gram polycoated aluminum tube with a white polyethylene tip and cap and protective band (NDC 42826-605-50).  For additional product information, please visit our website at www.siriontherapeutics.com or call our customer support number (1-866-4SIRION).  For sample requests please call 1-888-387-0853.

About Herpetic Keratitis

Herpetic Keratitis is the number one infectious cause of corneal blindness in the U.S.  Herpes simplex virus infections are very common, with nearly 60% of the US population showing evidence of infection by age five. Approximately 1% of infected patients develop ocular outbreaks, with 20,000 primary cases of ocular herpes diagnosed in the US each year. After the primary infection, ocular HSV typically becomes latent until triggers such as stress, UV radiation, and hormonal changes reactivate the virus and cause recurrent outbreaks. Those recurrences account for an additional 28,000 cases per year in the US. The risk of blindness increases with the number and severity of recurrences, making prompt treatment imperative to limit corneal scarring and other more serious ocular complications caused by herpetic ulcers.

About Zirgan™ (ganciclovir ophthalmic gel) 0.15%

Zirgan™ (ganciclovir ophthalmic gel) 0.15% is indicated for topical ophthalmic use as a treatment for acute herpetic keratitis (dendritic corneal ulcers).  Zirgan™ is an innovative topical antiviral therapy designed to specifically target herpes virus infected cells.  Zirgan™ has been a leading treatment for corneal ulcers, under the brand name Virgan®, in Europe for more than 10 years.  

The recommended dosing for Zirgan™ is one drop five times per day until the ulcer heals, and then one drop three times per day for seven days.  Zirgan™ is indicated for topical ophthalmic use only.  Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with Zirgan™. The most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).

About Sirion Therapeutics, Inc.

Sirion Therapeutics, Inc. is a privately held biopharmaceutical company located in Tampa, Florida.   For more information, please visit www.siriontherapeutics.com.


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
2. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Jan. 23, 2017 MouthWatch LLC announced today that ... ranked as the best intraoral camera on DentalCompare,s list of ... spot overall. The #1 product was the CollaPlug Absorbable ... intraoral camera was "…incredibly popular because it is by far ... a small sticker price, it doesn,t sacrifice quality imaging." ...
(Date:1/23/2017)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... primary and metastatic liver cancers, today announced that ... Chief Executive Officer of Delcath will be a featured ... Annual Investor Conference at the Boca Raton Resort & ... on Tuesday, January 31, 2017 at 10:30 am Eastern ...
(Date:1/23/2017)... DIEGO , Jan. 23, 2017  Using ... patients at high risk for acute kidney injury ... recommended by globally-recognized care guidelines significantly ... to severe AKI more than 33 percent, according ... in the journal Intensive Care Medicine. ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is proud ... Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This ... 2008 to address the limitations of fatigue monitoring technologies within the mining industry. ...
(Date:1/23/2017)... Washington, Dc (PRWEB) , ... January 23, 2017 ... ... at American University is taught by healthcare management and evaluation leaders with decades ... from fee-for-service to pay-for-value in the United States healthcare system, there is a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... (IHCA/INCAL), will serve as a healthcare industry expert at the 2017 Sector Summit ... moderated by Inside Indiana Business host Gerry Dick, will feature an employer and ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... has earned organic certification under the USDA National Organic Program (NOP) for its ... process, we have established organic production and handling systems to complement our current ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and ... Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality ...
Breaking Medicine News(10 mins):